Drug Formulary January 2020
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
January 2021 Update
PUBLISHED JULY 08, 2021 OCTOBER/DECEMBER 2020; JANUARY 2021 UPDATE CHANGES TO THE HIGHMARK DRUG FORMULARIES Following is the update to the Highmark Drug Formularies and pharmaceutical management procedures for January 2021. The formularies and pharmaceutical management procedures are updated on a bimonthly basis, and the following changes reflect the decisions made in October, December, and January by our Pharmacy and Therapeutics Committee. These updates are effective on the dates noted throughout this document. Please reference the guide below to navigate this communication: Section I. Highmark Commercial and Healthcare Reform Formularies A. Changes to the Highmark Comprehensive Formulary and the Highmark Comprehensive Healthcare Reform Formulary B. Changes to the Highmark Healthcare Reform Essential Formulary C. Changes to the Highmark Core Formulary D. Changes to the Highmark National Select Formulary E. Updates to the Pharmacy Utilization Management Programs 1. Prior Authorization Program 2. Managed Prescription Drug Coverage (MRxC) Program 3. Formulary Program 4. Quantity Level Limit (QLL) Programs As an added convenience, you can also search our drug formularies and view utilization management policies on the Provider Resource Center (accessible via NaviNet® or our website). Click the Pharmacy Program/Formularies link from the menu on the left. Highmark Blue Cross Blue Shield Delaware is an independent licensee of the Blue Cross and Blue Shield Association. NaviNet is a registered trademark of NaviNet, Inc., which is an independent company that provides secure, web-based portal between providers and health insurance companies. IMPORTANT DRUG SAFETY UPDATES 03/31/2021 – Studies show increased risk of heart rhythm problems with seizure and mental health medicine lamotrigine (Lamictal) in patients with heart disease. -
OUH Formulary Approved for Use in Breast Surgery
Oxford University Hospitals NHS Foundation Trust Formulary FORMULARY (Y): the medicine can be used as per its licence. RESTRICTED FORMULARY (R): the medicine can be used as per the agreed restriction. NON-FORMULARY (NF): the medicine is not on the formulary and should not be used unless exceptional approval has been obtained from MMTC. UNLICENSED MEDICINE – RESTRICTED FORMULARY (UNR): the medicine is unlicensed and can be used as per the agreed restriction. SPECIAL MEDICINE – RESTRICTED FORMULARY (SR): the medicine is a “special” (unlicensed) and can be used as per the agreed restriction. EXTEMPORANEOUS PREPARATION – RESTRICTED FORMULARY (EXTR): the extemporaneous preparation (unlicensed) can be prepared and used as per the agreed restriction. UNLICENSED MEDICINE – NON-FORMULARY (UNNF): the medicine is unlicensed and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. SPECIAL MEDICINE – NON-FORMULARY (SNF): the medicine is a “special” (unlicensed) and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. EXTEMPORANEOUS PREPARATION – NON-FORMULARY (EXTNF): the extemporaneous preparation (unlicensed) cannot be prepared and used unless exceptional approval has been obtained from MMTC. CLINICAL TRIALS (C): the medicine is clinical trial material and is not for clinical use. NICE TECHNOLOGY APPRAISAL (NICETA): the medicine has received a positive appraisal from NICE. It will be available on the formulary from the day the Technology Appraisal is published. Prescribers who wish to treat patients who meet NICE criteria, will have access to these medicines from this date. However, these medicines will not be part of routine practice until a NICE TA Implementation Plan has been presented and approved by MMTC (when the drug will be given a Restricted formulary status). -
Drug Pipeline Monthly Update June 2021
Drug Pipeline MONTHLY UPDATE Critical updates in an ever changing environment June 2021 NEW DRUG INFORMATION ™ ● Myfembree (relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5mg): The U.S. Food and Drug Administration (FDA) has approved Pfizer’s Myfembree (relugolix 40mg, estradiol 1mg, and norethindrone acetate 0.5mg), as a once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women, with a treatment duration of up to 24 months. Uterine fibroids are the most common benign tumors in women of reproductive age and are estimated to affect 20 to 60% of women by the time they reach menopause. The approval of Myfembree is supported by efficacy and safety data from two Phase 3 clinical trials, LIBERTY 1 and LIBERTY 2 which demonstrated a 72.1% and 71.2% response rate respectively in menstrual blood loss at week 24. Additionally, the combination therapy preserved bone mass density in the women enrolled in the clinical trials. Myfembree has launched with a wholesale acquisition cost (WAC) of $974.54 for a 28-day supply.1 ™ ● Lybalvi (olanzapine and samidorphan): The FDA has approved Alkermes’ Lybalvi for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. Lybalvi is a once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic agent, and samidorphan, a new chemical entity that is designed to mitigate weight gain associated with olanzapine. -
Drug-Induced Liver Injury (DILI): Current Status and Future Directions for Drug Development and the Post-Market Setting
Drug-induced liver injury (DILI): Current status and future directions for drug development and the post-market setting A consensus by a CIOMS Working Group Council for International Organizations of Medical Sciences (CIOMS) Geneva 2020 Drug-induced liver injury (DILI): Current status and future directions for drug development and the post-market setting A consensus by a CIOMS Working Group Council for International Organizations of Medical Sciences (CIOMS) Geneva 2020 Copyright © 2020 by the Council for International Organizations of Medical Sciences (CIOMS) ISBN: 978-929036099-5 All rights reserved. CIOMS publications may be obtained directly from CIOMS through its publications e-module at https://cioms.ch/publications/. Further information can be obtained from CIOMS, P.O. Box 2100, CH-1211 Geneva 2, Switzerland, tel.: +41 22 791 6497, www.cioms.ch, e-mail: [email protected]. CIOMS publications are also available through the World Health Organization, WHO Press, 20 Avenue Appia, CH-1211 Geneva 27, Switzerland. This publication is freely available on the CIOMS website at: https://cioms.ch/publications/product/drug-induced-liver-injury/ Suggested citation: Drug-induced liver injury (DILI): Current status and future directions for drug development and the post-market setting. A consensus by a CIOMS Working Group. Geneva, Switzerland: Council for International Organizations of Medical Sciences (CIOMS), 2020. Note on style: This publication uses the World Health Organization’s WHO style guide, 2nd Edition, 2013 (WHO/KMS/WHP/13.1) wherever possible for spelling, punctuation, terminology and formatting. The WHO style guide combines British and American English conventions. Disclaimer: The authors alone are responsible for the views expressed in this publication, and those views do not necessarily represent the decisions, policies or views of their respective institutions or companies. -
Appendix B - Product Name Sorted by Applicant
JUNE 2021 - APPROVED DRUG PRODUCT LIST B - 1 APPENDIX B - PRODUCT NAME SORTED BY APPLICANT ** 3 ** 3D IMAGING DRUG * 3D IMAGING DRUG DESIGN AND DEVELOPMENT LLC AMMONIA N 13, AMMONIA N-13 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18 3M * 3M CO PERIDEX, CHLORHEXIDINE GLUCONATE * 3M HEALTH CARE INC AVAGARD, ALCOHOL (OTC) DURAPREP, IODINE POVACRYLEX (OTC) 3M HEALTH CARE * 3M HEALTH CARE INFECTION PREVENTION DIV SOLUPREP, CHLORHEXIDINE GLUCONATE (OTC) ** 6 ** 60 DEGREES PHARMS * 60 DEGREES PHARMACEUTICALS LLC ARAKODA, TAFENOQUINE SUCCINATE ** A ** AAA USA INC * ADVANCED ACCELERATOR APPLICATIONS USA INC LUTATHERA, LUTETIUM DOTATATE LU-177 NETSPOT, GALLIUM DOTATATE GA-68 AAIPHARMA LLC * AAIPHARMA LLC AZASAN, AZATHIOPRINE ABBVIE * ABBVIE INC ANDROGEL, TESTOSTERONE CYCLOSPORINE, CYCLOSPORINE DEPAKOTE ER, DIVALPROEX SODIUM DEPAKOTE, DIVALPROEX SODIUM GENGRAF, CYCLOSPORINE K-TAB, POTASSIUM CHLORIDE KALETRA, LOPINAVIR NIASPAN, NIACIN NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE NIMBEX, CISATRACURIUM BESYLATE NORVIR, RITONAVIR SYNTHROID, LEVOTHYROXINE SODIUM ** TARKA, TRANDOLAPRIL TRICOR, FENOFIBRATE TRILIPIX, CHOLINE FENOFIBRATE ULTANE, SEVOFLURANE ZEMPLAR, PARICALCITOL ABBVIE ENDOCRINE * ABBVIE ENDOCRINE INC LUPANETA PACK, LEUPROLIDE ACETATE ABBVIE ENDOCRINE INC * ABBVIE ENDOCRINE INC LUPRON DEPOT, LEUPROLIDE ACETATE LUPRON DEPOT-PED KIT, LEUPROLIDE ACETATE ABBVIE INC * ABBVIE INC DUOPA, CARBIDOPA MAVYRET, GLECAPREVIR NORVIR, RITONAVIR ORIAHNN (COPACKAGED), ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE -
Brand-To-Generic Medication Reference
Brand Name Generic Name Absorica® Capsules Isotretinoin Capsules, USP Acanya® Gel Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% Accutane® Capsules Claravis™ (isotretinoin capsules, USP) Achromycin V® Capsules, USP Tetracycline Hydrochloride Capsules, USP Acticlate® Tablets Doxycycline Hyclate Tablets, USP Actigall® Capsules Ursodiol Capsules, USP ACTIQ® oral transmucosal lozenge Oral Transmucosal Fentanyl Citrate [C-II] (OTFC) Lozenges CII Activella® Tablets, 1 mg/0.5 mg Mimvey® (estradiol and norethindrone acetate tablets, USP) Actonel® Tablets Risedronate Sodium Tablets, USP Actos Tablets Pioglitazone Tablets, USP Adcirca® Tablets ALYQ™ (tadalafil tablets, USP) Adderall XR® Capsules [CII] Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Extended- Release Capsules CII Adderall® Tablets [CII] Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets CII Adenoscan® Injection Adenosine Injection, USP Adriamycin PFS® Injection Doxorubicin Hydrochloride Injection, USP Afinitor® Tablets Everolimus Tablets Agrylin® Capsules Anagrelide Capsules, USP Brand Name Generic Name AirDuo RespiClick® Inhalation Fluticasone Propionate and Powder Salmeterol Inhalation Powder (Multidose Dry Powder Inhaler) Albenza® Tablets Albendazole Tablets, USP Alesse® Tablets Aviane® (levonorgestrel and ethinyl estradiol tablets, USP) Alkeran® for Injection Melphalan Hydrochloride for Injection Aloxi® Injection Palonosetron Hydrochloride Injection Ambien® -
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
Effective 6/11/2020. Contact [email protected] for previous versions. Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline Note: Active Table of Contents – Click to follow link INTRODUCTION........................................................................................................................... 3 SCOPE....................................................................................................................................... 3 DEFINITIONS .............................................................................................................................. 3 RECOMMENDATIONS ................................................................................................................... 4 METHODOLOGY .........................................................................................................................28 COLLATERAL TOOLS & RESOURCES..................................................................................................31 APPENDIX A: PERIOPERATIVE MEDICATION MANAGEMENT .................................................................32 APPENDIX B: TREATMENT ALGORITHM FOR THE TIMING OF ELECTIVE NONCARDIAC SURGERY IN PATIENTS WITH CORONARY STENTS .....................................................................................................................58 APPENDIX C: METHYLENE BLUE AND SEROTONIN SYNDROME ...............................................................59 APPENDIX D: AMINOLEVULINIC ACID AND PHOTOTOXICITY -
Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
LEGEMIDDELSTATISTIKK 2019:2 Reseptregisteret 2014–2018 The Norwegian Prescription Database 2014–2018 Reseptregisteret 2014–2018 The Norwegian Prescription Database 2014–2018 Christian Lie Berg Kristine Olsen Solveig Sakshaug Utgitt av Folkehelseinstituttet / Published by Norwegian Institute of Public Health Område for Helsedata og digitalisering Avdeling for Legemiddelstatistikk Juni 2019 Tittel/Title: Legemiddelstatistikk 2019:2 Reseptregisteret 2014–2018 / The Norwegian Prescription Database 2014–2018 Forfattere/Authors: Christian Berg, redaktør/editor Kristine Olsen Solveig Sakshaug Acknowledgement: Julie D. W. Johansen (English text) Bestilling/Order: Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no / The report can be downloaded from www.fhi.no Grafisk design omslag: Fete Typer Ombrekking: Houston911 Kontaktinformasjon / Contact information: Folkehelseinstituttet / Norwegian Institute of Public Health Postboks 222 Skøyen N-0213 Oslo Tel: +47 21 07 70 00 ISSN: 1890-9647 ISBN: 978-82-8406-014-9 Sitering/Citation: Berg, C (red), Reseptregisteret 2014–2018 [The Norwegian Prescription Database 2014–2018] Legemiddelstatistikk 2019:2, Oslo, Norge: Folkehelseinstituttet, 2019. Tidligere utgaver / Previous editions: 2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007 2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008 2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende legemidler / The Norwegian -
Walterreedarmy June2021idx 1..16
NCR-JOA UNIFIED MEDICATION FORMULARY Alphabetical Listing by Therapeutic Category This document is current as of Aug. 23, 2021 The availability of formulary items is subject to change. ABORTIFACIENT Abortifacient Ammonium Detoxicant MiFEPRIStone ........................................................................................23 Lactulose ................................................................................................ 20 Neomycin ................................................................................................24 Acetylcholinesterase Inhibitor Neostigmine ............................................................................................25 AMPA Glutamate Receptor Antagonist Pyridostigmine ........................................................................................29 Perampanel ............................................................................................ 27 Acetylcholinesterase Inhibitor (Central) Amylinomimetic Donepezil ................................................................................................12 Pramlintide ..............................................................................................28 Galantamine ........................................................................................... 16 Rivastigmine ...........................................................................................30 Analgesic Combination (Opioid) Acetaminophen and Codeine ...................................................................2 Acne -
Brand Generic Guide
Table Of Contents Section 1 .................................................2-6 Introduction Section 2 ................................................7-14 Dr. Reddy’s Product Portfolio Section 3 ............................................. 15-52 Generic Names To Brand Names Section 4 ......................................... 53-90 Brand Names To Generic Names Section 5 ..........................................91-110 Clinical Resources 1 Dear Healthcare Professional, At Dr. Reddy’s North American Generics, we strive every day to do what matters most to patients –accelerating access to the affordable medicines they need, because Good Health Can't Wait. Each of us is driven by the urgency for good health and committed to providing you with the most affordable products at the best value every day. The medicines we provide to patients and our customers are among the more than 1000 products listed in the Dr. Reddy’s Brand-to-Generic-to-Brand Conversion Guide. The complimentary pocket guide features an easy-to-use conversion guide and other clinical resources to assist you with conversions, calculations, assessments and more. It includes: • Generic-to-Brand Conversion Guide An alphabetical listing of generic products, cross-referenced to the corresponding brand names • Brand-to-Generic Conversion Guide An alphabetical listing of brand products, cross-referenced to the corresponding generic names • Clinical Resource Section Resources such as charts on liver function assessment, equi-analgesic doses, and high-alert drugs • Product Portfolio The complete Dr. Reddy’s product portfolio is presented in Section 2 of the guide. Throughout the guide, Dr. Reddy’s products are printed in color. As the Brand-to-Generic-to-Brand Conversion Guide earns 1 its place as a valuable tool in your clinical setting, know that all of us at Dr. -
FEP 5 Tier Rx Drug Formulary (607) Standard Option
FEP 5 Tier Rx Drug Formulary (607) Standard Option Effective July 1, 2021 The FEP formulary includes the preferred drug list which is comprised of Tier 1, generics and Tier 2, preferred brand-name drugs. Also included in the formulary are Tier 3, non-preferred brand-name drugs, Tier 4, preferred specialty drugs and Tier 5, non-preferred specialty drugs. Ask your physician if there is a generic drug available to treat your condition. If there is no generic drug available, ask your physician to prescribe a preferred brand-name drug. The preferred brand-name drugs within our formulary are listed to identify medicines that are clinically appropriate and cost-effective. Click on the category name in the Table of Contents below to go directly to that page INTRODUCTION ........................................................................................................................................................................................................................ 5 PREFACE ................................................................................................................................................................................................................................... 5 EXCLUDED DRUGS .................................................................................................................................................................................................................. 6 PRIOR APPROVAL .................................................................................................................................................................................................................. -
List of Off-Patent, Off-Exclusivity Drugs Without an Approved Generic
List of Off-Patent, Off-Exclusivity Drugs without an Approved Generic To improve transparency and encourage the development and submission of abbreviated new drug applications (ANDAs) for drugs with limited competition, FDA is publishing a list, consistent with the methodology described below, of approved new drug application (NDA) drug products that are off-patent and off-exclusivity, and for which the FDA has not approved an ANDA referencing that NDA drug product. Part I of the list identifies those drug products for which FDA could immediately accept an ANDA without prior discussion. Part II identifies drug products for which ANDA development or approval may raise potential legal, regulatory, or scientific issues that should be addressed with the Agency prior to considering submission of an ANDA. The Appendix identifies NDA drug products that were removed from Part I or Part II of the list because one or more ANDAs referencing such NDA drug products have been approved since the previous list publication. Sponsors wishing to pursue approval of ANDAs referencing drug products identified in Part II of this list generally should submit an initial inquiry to the Office of Generic Drugs at [email protected]. Sponsors may be referred to the Office of New Drugs under certain circumstances, for example if the product is a biological product, or if the product is not eligible for submission or approval as an ANDA but may be considered for submission under another abbreviated approval pathway. Sponsors should identify the product’s established name and NDA number in any inquiry. • For some products in Part II of the list, submission and/or approval of an ANDA via the 505(j) pathway may not be appropriate; section 505(b)(2) of the FD&C Act may be an appropriate abbreviated approval pathway for such products.